Automated Method for Rapid Detection of Sickle Cell Disease Inhibitors
Description of Invention:
Available for licensing is a rapid and automated method for discovering potential drugs for the treatment of sickle cell anemia by determining the sickling times for a large population of red blood cells. The method uses a combination of laser photolysis and statistical processing of digital images. Sickle cell disease is an inherited disorder that affects over 70,000 Americans. The disease is characterized by presence of mutant hemoglobin S in red blood cells, which polymerizes to form fibers when deoxygenated. Such fibers lead to distortion of red blood cells into the shape of a sickle and alter the mechanical properties of these cells. Studies demonstrate that the time to polymerization involves a delay time and rapid growth phase and is particularly sensitive to hemoglobin concentration. As a result, identification of drugs that inhibit sickle cell disease is accomplished using an assay for delay times for populations of red blood cells. The invention creates a uniform time at which polymerization is initiated for all red blood cells in the sample region and accurately determines the time at which cellular distortion begins for each cell. Potential drugs are those compounds that significantly increase the delay time of sickling time, i.e. the time at which the cell changes shape due to intracellular polymerization.
Applications:
Rapid automated detection of compounds that inhibit sickling and are therefore potential drugs for sickle cell disease
Objective assay for monitoring disease severity
Development Status:
The technology is capable of determining the distribution of cellular delay times in a large number of samples in series in a 48 well plate format.
Patent Status:
DHHS Reference No. E-021-2007/0 --
U.S. Patent Application No. 11/652,843, filed 11 Jan 2007
PCT Application No. PCT/US2008/000427 filed 11 Jan 2008
Licensing Status: Available for licensing.
Collaborative Research Opportunity:
The NIDDK Laboratory of Chemical Physics is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Rochelle S. Blaustein, J.D. at 301-451-3636 or rochelle.blaustein@nih.gov more information.
Portfolios: Internal Medicine Devices/Instrumentation
For Additional Information Please Contact: Cristina Thalhammer-Reyero PhD MBA
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-4507
Email: thalhamc@mail.nih.gov
Fax: (301) 402-0220
